Crysvita
RxNorm 2043860

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2043860 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Crysvita.

The following semantic concepts and normalized strings are associated with this clinical entity:

BN
Crysvita
AUI:10268908
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

BNPrescribable

Brand Name (BN):
Crysvita
(Atom ID: 10268908)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Crysvita
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2043860
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10268908
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BN
Brand Name (A proprietary name for a family of products containing a specific active ingredient.)
Source Code
2043860
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN BN CARDINALITY
single
Cardinality of RxNorm Brand Name Atom

Patient Education

Burosumab-twza Injection


Burosumab-twza injection is used to treat X-linked hypophosphatemia (XLH; an inherited disease where the body doesn't maintain phosphorus and that leads to weak bones) in adults and children 6 months of age and older. It is also used to treat tumor-induced osteomalacia (a tumor that causes a loss of phosphorus in the body that leads to weak bones) that cannot be surgically removed in adults and children 2 years of age and older, Burosumab-twza injection is in a class of medications called fibroblast growth factor 23 (FGF23) blocking antibodies. It works by blocking the action of a certain natural substance in the body which causes the symptoms of XLH.
[Learn More]


* Please review the disclaimer below.